InClinica Expands American Operations
Global Clinical CRO hires two executives, promotes new Vice President
PHILADELPHIA (JUNE 20, 2017) – InClinica, a global, clinical CRO, announced that it has hired two new executives, Paul Dick as Vice President of Business Development and John “Jack” Chabala, Ph.D. as Chief Technical Analyst, and promoted current executive Danielle Bradbury to Vice President and General Manager of the Americas to strengthen its U.S. presence.
“We are excited to continue to build such a knowledgeable, talented team here in the United States,” said James Nolan, CEO at InClinica. “Paul, Jack and Danielle all possess extensive industry experience that will be a great asset to the company, and we look forward to working with them to further our mission of helping our clients achieve regulatory approval.”
In his role as Vice President of Business Development, Paul will be responsible for growing InClinica’s presence in the clinical trial business segment and introducing clients to its global team and expert approach to clinical development. He brings more than 25 years of experience in the life sciences industry, serving in various leadership positions including Sr. Director USA Sales, Global Market Measurement at QuintilesIMS. Paul holds a Master of Business Administration from La Salle University and a dual Bachelor of Science in marketing and management information systems from Indiana University of Pennsylvania.
Jack joins InClinica with more than 40 years of medicinal chemistry experience. Throughout his career, he has served in many operations-related leadership positions for life sciences companies. He is the co-inventor of ivermectin, a highly successful parasiticide for which he received the Thomas Alva Edison Patent Award in 1987 and the New Jersey Institute of Chemistry Award in 1992. The 2015 Nobel Prize in Physiology and Medicine was awarded, in part, for its use in treating onchocerciasis and filariasis in humans. Jack holds doctorate in organic chemistry from Massachusetts Institute of Technology and a Bachelor of Science in chemistry from Bucknell University.
Promoted to Vice President, General Manager of the Americas from her previous role as Senior Director of Quality Assurance, Danielle will be responsible for the performance of the clinical operations, project management, and administrative teams. She has more than 15 years of experience in the pharmaceutical industry. Previously, Danielle oversaw the quality assurance of all clinical trial-associated activities and records for InClinica and other companies. She holds a Bachelor of Science in nursing from Wilmington University.
InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in the U.K., Israel, and Malaysia/Singapore.